Association of Gamma-glutamyl Transferase Concentrations with All-cause and Cause-specific Mortality in Chinese Adults with Type 2 Diabetes

Overview

Journal J Diabetes

Specialty Endocrinology

Date 2023 May 10

PMID 37161588

Authors

Haoyu Guan

Ke Liu

Xikang Fan

Hao Yu

Yu Qin

Jie Yang

Zheng Zhu

Chong Shen

Enchun Pan

Yan Lu

Jinyi Zhou

Jian Su

Ming Wu

Affiliations

Soon will be listed here.

Abstract

Background: Evidence links gamma-glutamyl transferase (GGT) to mortality in the general population. However, the relationship of GGT with all-cause and cause-specific mortality risk has been little explored in type 2 diabetes mellitus (T2DM) patients.

Methods: We recruited 20 340 community-dwelling T2DM patients between 2013 and 2014 in Jiangsu, China. Cox regression models were used to assess associations of GGT with all-cause and specific-cause mortality. Restricted cubic splines were used to analyze dose-response relationships between GGT and mortality. Stratified analysis was conducted to examine potential interaction effects by age, sex, smoking status, body mass index (BMI), diabetes duration, and dyslipidemia.

Results: During a median follow-up period of 7.04 years (interquartile range: 6.98-7.08), 2728 deaths occurred, including 902 (33.09%) due to cardiovascular disease (CVD), and 754 (27.58%) due to cancer. GGT concentrations were positively associated with all-cause, CVD, and cancer mortality. Multivariable hazard ratios (HRs) for the highest (Q5) vs. the lowest quintile (Q1) were 1.63 (95% confidence intervals [CI]: 1.44-1.84) for all-cause mortality, 1.87 (95% CI: 1.49-2.35) for CVD mortality, and 1.43 (95% CI: 1.13-1.81) for cancer mortality. Effect modification by BMI and dyslipidemia was observed for all-cause mortality (both p for interaction <.05), and HRs were stronger in the BMI <25 kg/m group and those without dyslipidemia.

Conclusions: Our findings suggest that, in Chinese T2DM patients, elevated serum GGT concentrations were associated with mortality for all-cause, CVD, and cancer, and further research is needed to elucidate the role of obesity, nonalcoholic fatty liver disease, and lipids in this association.

Citing Articles

The Jiangsu Biobank for the Prevention and Control of Diabetes (JBPCD) in China.

Su J, Hang D, He J, Yang J, Pan E, Lu Y Eur J Epidemiol. 2024; 39(11):1287-1295.

PMID: 39565534 DOI: 10.1007/s10654-024-01172-y.

Gamma-glutamyl transferase and the risk of all-cause and disease-specific mortality in patients with diabetes: A nationwide cohort study.

Chung G, Jeong S, Yu S, Yoo J, Cho Y, Lee K J Diabetes. 2024; 16(5):e13551.

PMID: 38664890 PMC: 11045922. DOI: 10.1111/1753-0407.13551.

Association of gamma-glutamyl transferase concentrations with all-cause and cause-specific mortality in Chinese adults with type 2 diabetes.

Guan H, Liu K, Fan X, Yu H, Qin Y, Yang J J Diabetes. 2023; 15(8):674-684.

PMID: 37161588 PMC: 10415869. DOI: 10.1111/1753-0407.13399.

References

Oh C, Won Y, Cho H, Lee J, Park B, Jun J . Alanine aminotransferase and gamma-glutamyl transferase have different dose-response relationships with risk of mortality by age. Liver Int. 2015; 36(1):126-35. DOI: 10.1111/liv.12879. View

Sung K, Ryu S, Kim B, Cheong E, Park D, Kim B . γ-Glutamyl Transferase Is Associated with Mortality Outcomes Independently of Fatty Liver. Clin Chem. 2015; 61(9):1173-81. DOI: 10.1373/clinchem.2015.240424. View

Williams K, Sullivan D, Nicholson G, George J, Jenkins A, Januszewski A . Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 2016; 65(5):783-793. DOI: 10.1016/j.metabol.2015.12.008. View

Targher G, Arcaro G . Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2006; 191(2):235-40. DOI: 10.1016/j.atherosclerosis.2006.08.021. View

Pompella A, Corti A, Paolicchi A, Giommarelli C, Zunino F . Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr Opin Pharmacol. 2007; 7(4):360-6. DOI: 10.1016/j.coph.2007.04.004. View

Guan H, Liu K, Fan X, Yu H, Qin Y, Yang J . Association of gamma-glutamyl transferase concentrations with all-cause and cause-specific mortality in Chinese adults with type 2 diabetes. J Diabetes. 2023; 15(8):674-684. PMC: 10415869. DOI: 10.1111/1753-0407.13399. View

Lee D, Silventoinen K, Hu G, Jacobs Jr D, Jousilahti P, Sundvall J . Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J. 2006; 27(18):2170-6. DOI: 10.1093/eurheartj/ehl086. View

Hernaez R, Yeh H, Lazo M, Chung H, Hamilton J, Koteish A . Elevated ALT and GGT predict all-cause mortality and hepatocellular carcinoma in Taiwanese male: a case-cohort study. Hepatol Int. 2015; 7(4):1040-9. DOI: 10.1007/s12072-013-9476-6. View

Stefan N, Cusi K . A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022; 10(4):284-296. DOI: 10.1016/S2213-8587(22)00003-1. View

10.

Chiang C, Lee L, Hung S, Lin W, Hung H, Yang W . Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly. Hepatology. 2014; 59(6):2207-15. DOI: 10.1002/hep.27014. View

11.

Roden M, Shulman G . The integrative biology of type 2 diabetes. Nature. 2019; 576(7785):51-60. DOI: 10.1038/s41586-019-1797-8. View

12.

Ho F, Ferguson L, Celis-Morales C, Gray S, Forrest E, Alazawi W . Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. EClinicalMedicine. 2022; 48:101435. PMC: 9112033. DOI: 10.1016/j.eclinm.2022.101435. View

13.

Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor D . Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2007; 27(12):2729-35. DOI: 10.1161/ATVBAHA.107.152298. View

14.

Sluik D, Boeing H, Montonen J, Pischon T, Kaaks R, Teucher B . Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am J Epidemiol. 2011; 174(1):22-34. DOI: 10.1093/aje/kwr048. View

15.

Kengne A, Czernichow S, Stamatakis E, Hamer M, Batty G . Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British Health Surveys. J Hepatol. 2012; 57(5):1083-9. DOI: 10.1016/j.jhep.2012.06.034. View

16.

Franzini M, Corti A, Martinelli B, Del Corso A, Emdin M, Parenti G . Gamma-glutamyltransferase activity in human atherosclerotic plaques--biochemical similarities with the circulating enzyme. Atherosclerosis. 2008; 202(1):119-27. DOI: 10.1016/j.atherosclerosis.2008.03.023. View

17.

Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L . Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014; 513(7516):59-64. DOI: 10.1038/nature13568. View

18.

Monami M, Balzi D, Lamanna C, Melani C, Cocca C, Lotti E . Prognostic value of serum liver enzymes levels in type 2 diabetic patients. Diabetes Metab Res Rev. 2007; 23(8):625-30. DOI: 10.1002/dmrr.744. View

19.

Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister S, Volzke H . Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology. 2009; 50(5):1403-11. DOI: 10.1002/hep.23135. View

20.

Martin I, Grotewiel M . Oxidative damage and age-related functional declines. Mech Ageing Dev. 2006; 127(5):411-23. DOI: 10.1016/j.mad.2006.01.008. View